CDMO Catalent has announced its acquisition of particle size reduction specialist Micron Technologies, which offers micronization, milling, and particle characterization services for pharmaceutical products, including inhalation powders. Catalent notes that it offers development through to commercial manufacturing for inhaled products, including potent compounds.
In March 2013, Micron Technologies announced that it had been acquired by a private equity firm. The company has approximately 100 employees at cGMP facilities in Malvern, PA and Dartford, UK.
Micron Technologies CEO Joseph Drost said, “We are excited to become part of Catalent, as there is a natural synergy between our organizations, with the global leader in advanced delivery technologies and development solutions now joining forces with a leading provider of particle size engineering technologies and integrated analytical services. Through access to Catalent’s global network, development expertise and innovative technologies, we can jointly provide end-to-end solutions to accelerate drug development programs and bring better treatments to patients worldwide.”
Catalent, Inc. President and CEO John Chiminski commented, “This strategic acquisition allows Catalent to provide an unprecedented set of integrated development solutions and superior drug delivery technologies to the industry, partnering with our customers’ R&D teams earlier in the development cycle and helping them deliver better treatments to clinic and to market faster and more efficiently. We are pleased to add Micron Technologies’ leading technologies and manufacturing expertise and welcome their highly talented management, scientific and operations teams to Catalent.”
Read the Catalent press release.
